Parker Institute for Cancer Immunotherapy Merges with Cancer Vaccine Coalition to Accelerate Cancer Vaccine Development
Event summary
- Parker Institute for Cancer Immunotherapy (PICI) integrates with Cancer Vaccine Coalition to accelerate cancer vaccine research and development.
- Kristen Dahlgren, founder of Cancer Vaccine Coalition, joins PICI as Chief External Affairs Officer.
- The partnership aims to bridge the gap between scientific discovery and patient access for cancer vaccines.
- PICI has supported over 1,000 investigators and has a portfolio of 17 biotech ventures with over $4B raised in capital.
The big picture
The strategic integration of PICI and the Cancer Vaccine Coalition comes at a time of significant momentum in cancer vaccine research, marked by scientific breakthroughs and growing investment. This partnership aims to leverage the strengths of both organizations to accelerate the development and delivery of cancer vaccines, addressing a critical need in cancer prevention and treatment. The combined entity will support high-impact research, advance clinical trials, and back the most promising vaccine strategies, particularly for patients at high risk of cancer recurrence.
What we're watching
- Research Acceleration
- How the combined efforts of PICI and the Cancer Vaccine Coalition will accelerate the development of cancer vaccines.
- Patient Access
- Whether the partnership can effectively bridge the gap between scientific discovery and patient access for cancer vaccines.
- Funding Momentum
- The pace at which increased investment and public support will drive further advancements in cancer vaccine research.
Related topics